Centocor to launch Myoscint myocardial infarction imaging agent in early 1997.
This article was originally published in The Gray Sheet
CENTOCOR MYOSCINT CARDIAC IMAGING AGENT EXPECTED TO LAUNCH IN EARLY 1997 following approval of the murine monoclonal antibody product in July. Myoscint is indicated for "preparation of Indium In 111 imciromab pentetate to be used as a cardiac imaging agent for detecting the presence and/or identifying the location of myocardial injury in patients with suspected myocardial infarction," FDA's July 3 approval letter states. Myoscint in vivo localizes in infarcted myocardial tissues.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.